Best in Biotech 16 Jan 2024
Five biotech companies taking Florida by storm
Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies.
Cancer
- Latest Posts
Best in Biotech 20 Dec 2023
Wrapping up 2023: A recap of top biotech moments of this year
2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023.
Best in Biotech 19 Dec 2023
Nine biotech companies to watch in 2024
2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
Opinion 18 Dec 2023
What to expect from biotech clinical trials in the coming year
As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024.
Best in Biotech 14 Dec 2023
Seven companies shaping the future of precision medicine
Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine.
More News! 4 Dec 2023
FDA CAR-T cell therapy warning: Are T cells malignant?
Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 23 Nov 2023
The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy
Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]
News and Trends 20 Nov 2023
M&As: what’s up with the ADC buying spree?
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]
Opinion 1 Nov 2023
Could this be the start of a new era for PI3K drugs?
There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […]
Podcast 27 Oct 2023
Beyond Biotech podcast 69 – improving access to cell and gene therapy
This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […]
In Depth 13 Oct 2023
How close are we to a cure for metastatic breast cancer?
Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […]
Podcast 13 Oct 2023
Beyond Biotech podcast 67 – natural killer cells
This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […]
ADVERTISEMENT
